Membrane binding proteins of coronaviruses

Entedar AJ Alsaadi1,2 & Ian M Jones*,1
1Biomedical Sciences, School of Biological Sciences, University of Reading, Reading RG6 6AJ, UK
2Department of Microbiology, College of Medicine, Thiqar University, Thiqar, Iraq
*Author for correspondence: i.m.jones@rdg.ac.uk

Coronaviruses (CoVs) infect many species causing a variety of diseases with a range of severities. Their members include zoonotic viruses with pandemic potential where therapeutic options are currently limited. Despite this diversity CoVs share some common features including the production, in infected cells, of elaborate membrane structures. Membranes represent both an obstacle and aid to CoV replication – and in consequence – virus-encoded structural and nonstructural proteins have membrane-binding properties. The structural proteins encounter cellular membranes at both entry and exit of the virus while the nonstructural proteins reorganize cellular membranes to benefit virus replication. Here, the role of each protein in membrane binding is described to provide a comprehensive picture of their role in the CoV replication cycle.

First draft submitted: 20 August 2018; Accepted for publication: 19 February 2019; Published online: 29 April 2019

Keywords: bending • coronavirus • egress • fusion • membrane • peptide • replication • web

Coronaviruses (CoVs) are enveloped positive sense RNA viruses causing a variety of diseases in man and animals and are considered to be the largest of the RNA viruses, with genomes ranging from 27–32 kb [1]. CoVs belong to the Coronaviridae family and contain two subfamilies Orthocoronavirinae and Letovirinae. Further, the Coronaviridae family is grouped into the suborder Cornidovirinae, which together with the suborders Abnidovirinae, Arnidovirinae, Mesnidovirinae, Monidovirinae, Ronidovirinae and Tornidovirinae forms the Nidovirales order [1,2], so named for the overlapping set of transcripts used by all members to encode viral proteins. The Coronaviridae are further subdivided phylogenetically into four genera, α, β, γ and δ [3]. The CoVs include members classified as emerging viruses, viruses that are able to cross the species barrier and cause pathology in a new target species. Two such recent events are the highly pathogenic severe acute respiratory syndrome-related CoV (SARS-CoV) that emerged in Southern China in 2003 and Middle East respiratory syndrome-related CoV (MERS-CoV), which appeared in Saudi Arabia in 2012 [4,5]. There is no effective treatment or licensed vaccine for either virus, which emphasizes the need to further understand CoV biology as a route to improved future intervention [6,7].

CoVs are structurally complex (Figure 1) with purified virus particles consisting of four or five structural proteins along with a variety of minor components including nonstructural and host cell-derived proteins [8]. All viruses have Nucleocapsid (N), Spike (S), Envelope (E) and Membrane (M) structural proteins and some also encode a hemagglutinin–esterase (HE) protein [1]. Despite their complexity and range of function however, [9,10] the structural proteins of CoVs occupy only about a third of the coding capacity of the genome. A much larger section of the genome, some two-thirds located at the 5′ end encode two long open reading frames 1a and 1b that together encode the nonstructural proteins of the virus. Each sequence is translated first as a polyprotein precursor, pp1a and pp1ab, the latter achieved by a frameshift event at the end of the 1a coding sequence. The polyproteins include several viral proteases that together process pp1a and pp1ab into 16 nonstructural proteins (nsp1–16), which are required at various stages of the virus replication cycle [1]. As an enveloped virus, the virus surface proteins, S, M and E encounter cellular membranes at the initiation of infection, again during the replication cycle when they are translated and incorporated into the endoplasmic reticulum and endoplasmic reticulum Golgi intermediate compartment (ERGIC) [11,12] and finally in the secretory pathway where budding of the mature virions occurs (Figure 2) [9,13]. In addition, many of the nonstructural proteins also interact with membranes as, in common with
other positive strand RNA viruses, virus replication takes place in specialized cellular compartments induced by viral proteins which modify host membranes or organelles to set up sites for replication that are hidden from the cellular inducers of innate immunity [14]. The combination of multiple membrane interacting factors and multiple sites of membrane interaction make CoVs one of the more challenging virus-membrane interaction models available.

Structural protein interactions

The fusion process between viral and host membranes, mediated in CoVs by the S protein, is a crucial step in enveloped virus infection [15,16]. The S protein is a large class I fusion protein responsible for virus binding to target cells via cell surface receptors, which for CoVs can range from simple sugars to complex proteins (reviewed in [17,18]). For example the entry receptor for MERS-CoV infection has been identified as dipeptidyl peptidase-4 (DPP4) found on a variety of cell types including epithelial cells of the respiratory tract [19]. As a result, receptor distribution and the CoV–S-receptor interaction often defines tissue tropism and host range [18,19].

The S protein consists of two subunits, S1 and S2, with S1 at the N-terminus providing the receptor binding function and S2 at the C-terminus providing fusion activity [15]. The subunits are cleaved from the complete S by host cell proteases including members of the cathepsin family and transmembrane protease serine 2 (TMPRSS2) [20]. Following receptor binding by S1 and uptake into a vesicle the fusion mechanism of S2 acts to bring the viral and cellular membranes into such close proximity that fusion occurs [21,22]. The S2 sequence contains conserved regions that are necessary for function, notably a fusion peptide and two conserved heptad repeats (HR) [18]. Briefly, significant conformational change occurs in the late clathrin-coated endocytosed vesicle leading to release of the fusion peptide to interact with the vesicle membrane, provided that S has been cleaved into its requisite subdomains [23]. The collapse of S2, which is now bridging the virus and cellular membranes, pulls the two membranes together with HR1 and HR2 forming the canonical 6-helix bundle first described for CoVs in mouse hepatitis virus (MHV) [24].

In terms of sequence and location precise fusion peptides (FP) have yet to be defined for all CoVs [25] as recognition of the FP motif within the large spike protein can be difficult. However, bioinformatics analysis suggests that at least part of the fusion peptide is located near the N-terminus of S2 where a conserved motif with properties consistent with those expected of an FP, IEDLLF, occurs across the CoV family. This motif demonstrates very little variation and when substitutions are found, they are conservative replacements consistent with an essential function [26,27]. The motif is not located at the N-terminus of HR1 as suggested in some S protein cleavage maps (e.g., ref [21])
Membrane binding proteins of coronaviruses

Su et al.

Receptor binding
Endocytosis
Fusion and genome release
Endoplasmic reticulum
Nucleus
DMVs
ER
Golgi
Maturation
Structural protein N
Structural proteins E, M, S
RNP assembly
 Trafficking and budding

Figure 2. The coronavirus replication cycle highlighting areas where membrane interaction occurs. (1) Most coronaviruses enter by receptor mediated endocytosis. The positive sense genomic RNA is released into the cytoplasm and translated into the initial virus polyproteins which encode the nsp. (2) The nsp stimulate the production of DMVs and establish the replication transcription complexes (RTC), which produce the -ve strand replicative intermediate from which more +ve strand genomes and mRNAs are produced. Translation of the N mRNA produces the N protein in the cytoplasm which combines with the new genomes to form RNP while translation of the remaining structural proteins, M, E and S occurs in the ER where they accumulate in the ERGIC and cis-Golgi. (3) Virus assembly begins and completes as the protein cargos migrate through the Golgi stacks resulting in new virus particles in vesicles (4), which eventually fuse with the plasma membrane.

DMV: Double-membrane vesicle; ER: Endoplasmic reticulum; ERGIC: Endoplasmic reticulum Golgi intermediate compartment; nsp: Nonstructural protein; RTC: Replication transcription complex.

but immediately follows the second, S2' cleavage site, originally mapped in SARS-CoV S and later in MERS-CoV S [26,28,29]. A sequence which includes this motif has been shown directly for SARS-CoV to act as a fusion peptide when tested in an in vitro binding assay with multilamellar vesicles (MLVs) where it reorders membranes in a calcium-dependent manner [30].

The endodomain of S2 can be subdivided into two regions, a cysteine-rich region at the N-terminus and a carboxy-terminal region rich in charged residues [31–33]. It has been shown that clusters of cysteine residues are important for the palmitoylation of S. No particular cysteine residue is critical but in a study of fusion competence and replication in MHV a total of at least three cysteine residues was required [34] and other studies have confirmed that the cysteine-rich region is necessary for syncytium formation during viral infection [35,36]. While membrane binding and deformation is clearly a property of the FP sequence, propelled into the membrane by the conformational changes in S, palmitoylation of S may serve to stabilize the protein during its interactions with lipid rafts in the target membranes to allow time for fusion to occur. Recently, several CoV-S proteins including HCoV-HKU1, MHV, HCoV-NL63, SARS-CoV and MERS-CoV have had their structures solved at atomic resolution following imaging with cryo-electron microscopy [37–40]. All the confirmed structures of S are in their prefusion state and most have had their cleavage sites mutated to enhance S stability in order to enable the imaging process. As a result there is limited knowledge of the CoV FP within the fusion active conformation or of its structural characteristics when interacting with lipid bilayers after proteolytic processing at the S2' site [30,38,40].

By contrast with S, the CoV envelope protein (E) is a small hydrophobic integral membrane protein ranging from 76 to 109 amino acids. It has an N-terminal domain, a long α-helical transmembrane domain and a C-terminal hydrophilic domain and is found as a minor component in all CoV groups [41,42]. The E protein is also palmitoylated.
Indeed, expression of just these proteins will induce the formation of the double-membrane vesicles required for the establishment of viral replication–transcription complexes (RTCs), also called replication organelles, in maintaining bioactive conformation and antigenic character [63,64]. M is located among the S proteins in the DMVs and other structures that are characteristic of CoV-infected cells [69]. Replication complexes, intimately associated at all three of its Cys residues [43] but the role of this secondary modification is debated. For MHV-CoV, single Cys residue changes do not significantly impair virus growth but modification of all three residues results in severe attenuation [44,45]. For SARS-CoV; however, triple mutation of the conserved Cys' does not impact secretion of virus antigen from expressing cells suggesting no particular dependence on palmitoylation [46]. Two membrane topologies have been demonstrated for E protein, hairpin or transmembrane, and it has been suggested that the level of palmitoylation may moderate their relative proportion, in turn allowing modified membrane curvature [45,47]. The E protein has demonstrated functions in virus assembly and release (below) and it appears to induce membrane curvature in the ERGIC leading to membrane scission of the budding virus particle and its release [48]. Envelope protein also interacts with the M protein and mutants of M that are unable to bud from cells can be complemented by mutated forms of E [49,50]. The membrane curving properties of E are such that co-expression of M and E is adequate for the efficient formation of virus-like particles [48,51], which can also incorporate S if it is co-expressed [52]. For many CoVs, including MHV, E protein has also been shown to have a role as an ion channel, a viroporin [53,54]. E function as a viroporin, including the trafficking of virions in the secretory pathways and membrane permeability, is essential for virus growth [55]. E also interacts with host cellular proteins including Proteins Associated with Lin Seven 1 (PALS1), which is known to maintain the epithelial cell junction, with clear implications for the virus assembly site in the Golgi [56,57]. While E function is critical for virus assembly, its viroporin activity in mobilizing calcium ions and its interactions with host tight junction cell proteins has been also implicated as a mediator of pathology in some CoV infections [55,57].

The CoV membrane protein (M) is a type III transmembrane glycoprotein and is the most abundant glycoprotein in the CoV particle. Despite variability in the primary M protein sequence the predicted secondary structures of M proteins are maintained [58]. The M protein is approximately 230 amino acids in length and is composed of three parts: a short N-terminal domain situated outside the virion membrane, three transmembrane domains and a carboxy-terminal domain situated inside the particle [59,60]. An amphipathic region situated at the end of the third transmembrane domain is well conserved in almost all Coronaviridae members [58]. CoV M proteins are characterized by N-linked glycosylation in the α and δ CoVs and O-linked glycosylation in the β CoVs [61,62] and study of chimeric M proteins has shown that the type of glycosylation is not critical for virus assembly or growth at 37°C [50]. It seems more likely that, as for many virus glycoproteins, glycosylation has a more general significance in maintaining bioactive conformation and antigenic character [63,64]. M is located among the S proteins in the virus envelope along with small amounts of E and is the primary driver of the virus budding process [51]. During assembly of the authentic virion M interacts with itself, with the nucleocapsid protein N, with E and with the S protein [44,58,65]. M protein is present as a dimer in the virion and high resolution imaging has suggested that it presents as two conformations, long and compact (M LONG and M COMPACT), which together induce membrane curvature as well as binding to the nucleocapsid [66,67].

Nonstructural protein interactions

CoV nsp 3, 4 and 6 (Figure 3) have fundamental functions in the rearrangement of host cell membranes that are required for the establishment of viral replication–transcription complexes (RTCs), also called replication organelles (RO) [68]. Indeed expression of just these proteins will induce the formation of the double-membrane vesicles (DMVs) and other structures that are characteristic of CoV-infected cells [69]. Replication complexes, intimately bound up with convoluted membrane structures, are a feature of all positive strand RNA viruses and serve at least three functions, probably connected. First, they serve to concentrate viral proteins in a microenvironment where all necessary replication factors are closely associated with the genomic RNA. Second, they exclude host factors so that the competition for resources can be focused on the virus and third they act to separate, as far as possible, the intermediates of replication, which are necessarily double stranded RNA molecules, from the host innate sensors such as TLR7 and MDA-5 [70,71].

Nsp3 has two membrane regions and approximately 10–16 identifiable domains (depending on the virus) within the approximately 200 kDa predicted primary translation product, eight of which are conserved [72]. It is co-translationally inserted into the endoplasmic reticulum resulting in the majority of the domains being tethered to the cytosolic side of the membrane (Figure 3). Nsp3 function is integral to CoV replication and its domains include many predicted or demonstrated to act as accessories in RNA replication such as sRNA binding and unwinding domains, as well as those for which no distinct function has yet been determined [72].

The 44 kDa CoV nsp4 protein is also a transmembrane protein, with four transmembrane helices and an internal C-terminal domain (Figure 3) and with nsp3 is an indispensable component required to produce DMVs [73,74]. All
CoV-nsp4 molecules encode at least one predicted glycosylation site and in the case of MHV, it has been shown that mutation of the glycosylation site results in loss of virus fitness suggesting that nsp4 glycosylation is necessary for virus replication or the organization of the DMVs [75]. In an electron micrographic study, transfection of SARS-nsp3 and nsp4 alone caused considerable membrane deformation, producing a perinuclear double-walled maze-like body (MLB) [76] and the nsp3–nsp4 interaction was shown to be absolutely necessary for such membrane rearrangement. However, the interaction of these two nsps was insufficient in itself to trigger membrane rearrangement and host factors such as EDEM1 and OS9 of the ER-associated degradation system have been shown to be co-factors [77,78]. Despite them being a universal feature of CoVs the size and number of DMVs does not appear to correlate directly with viral fitness, at least when virus is grown at reduced temperatures [79] nor are they a determinant of pathogenicity [80]. For the γ CoV Infectious Bronchitis Virus (IBV), nsp4 was essential and sufficient to induce membrane pairing, recognized as extensive areas of membrane accumulation or small regions of paired membrane, but expression of nsp3, nsp4 and nsp6 was required for DMV production which, even then, was poor for strain BeauR and not seen at all for strain M41. DMVs formed by IBV nsp3, nsp4, and nsp6 alone were poorly efficient when compared with DMVs formed by Betacoronavirus infection so supplementation of nsp4 with nsp6 is not sufficient for authentic IBV DMV production [81].

CoV nsp6 is a membrane protein of approximately 34 kDa predicted molecular mass with six transmembrane helices (Figure 3) including, in almost all viruses, a highly conserved C-terminus [82]. Although nsp6-stimulated internal cellular membrane rearrangement is observed with the addition of nsp3 and 4, nsp6 also causes membrane proliferation alone, including the formation of Atg5 and LC3II-positive vesicles classically observed in autophagy [83]. The autophagosomes produced are somewhat different from those induced by starvation; however, as although their number is higher and their size is reduced [84]. As noted above, along with nsp3 and 4, nsp6 functions to produce the canonical DMVs as well as many other types of intracellular vesicles observed in CoV infected cells such as convoluted membranes, vesicle packages, tubular bodies, large virion-containing vacuoles (LVCVs), cubic membrane structures (CMSs) and zippered ER spherules in the case of IBV [85,86]. An attenuated form of an IBV vaccine includes mutations in an nsp6 TM domain, confirming its role in virulence and replication [87].

**Recruitment & modification of membranes by CoVs**

As noted above, the membranous vesicles or organelles of different morphologies induced by CoVs act as a platform for the formation of replication–transcription complexes ( RTCs) and sequester newly formed RNAs away from host immune sensors [88,89]. Both viral and hijacked host proteins are used in this process, taking advantage of cellular pathways and lipid modifying enzymes to the benefit of the virus [90,91]. This usurping comes about through the
commandeering of normal secretory pathways used by noninfected cells to transport and deliver protein cargos; rather than encode proteins to build DMVs anew, CoVs redirect and reorganize the cellular processes already in place [92].

Two principle mechanisms have been described for moving and delivering cargo proteins through the secretory pathway; cisternal maturation and the formation of megavesicles [93]. In both cases the detail remains incomplete [94]. During CoV infection, such as for MHV, virions have been observed in large vesicle depots resembling megavesicles derived from Golgi/ERGIC membranes, indicating that remodeling of the Golgi complex may be crucial for virion trafficking [14]. As noted, nsp6 may initiate cellular autophagy and a general ER stress response also occurs during the formation of DMVs [95,96]. Atg5 is necessary for the formation the crescent membranes and if is knocked out the yield of MHV is reduced although this is not a universal finding [97]. Although the precise mechanisms are ill defined, biological bilayers of proteins and lipids [98] are key to the separation and control of biological processes and their occurrence and composition is dynamic [99]. Bending, that is positive or negative membrane curvature, is driven by the acquisition and loss of peripheral membrane proteins, integral membrane proteins and by lipid composition [100,101]. Membrane wrapping may occur around intrinsically curved proteins in which positively charged amino acids interact with negatively charged lipid head groups, for example, in the dynamin and BAR domain interactions, also known as scaffolding ([102,103]). Alternatively, crowding mechanisms may effect membrane curvature as a result of the asymmetric distribution of proteins either side of a cellular membrane [99,104], and the insertion of an amphipathic helix which can act as a wedge to expand one side of the membrane more than the other can also cause curvature as revealed by studies on influenza virus M2 protein, Epsins and Sar 1p [102,105,106].

Virus egress

During assembly, all enveloped viruses face the challenge of combining capsids proteins and genome produced in the cytosol with glycoproteins that predominantly occur in another cellular compartment, the luminal side of the ER. A cell membrane separates these components and must be breached or used in the assembly of the complete virion and this is achieved in three stages (Figure 2). First, the virus proteins coalesce on the membrane, capsid proteins grouping together underneath the patch of membrane where viral glycoproteins are embedded. Second, the membrane bulges outward to form a bud decorated by the viral transmembrane proteins and enclosing the capsid proteins and genome. Third and finally, the bud splits from the rest of the membrane by scission, a pinching-off at the base which releases the virion either into an intracellular vesicle as in the case for CoVs or directly out of the cell [1]. For many enveloped viruses these processes are actioned by viral protein interaction with host proteins of the endosomal sorting complexes required for transport (ESCRT) machinery [107]. Surprisingly however, perhaps because of incompatibility with the extensive membrane rearrangements induced in infected cells, CoVs appear not to use ESCRT proteins for egress, rather the S protein has a signal for ERGIC retention in its cytoplasmic tail [108] while the M protein locates to the ERGIC and cis-Golgi via its first TM domain where it also oligomerises [109] to drive the budding process. M–N interactions ensure that the viral RNPs also occur at these budding sites allowing the budding virus to incorporate a copy of the new genome [46,110]. The E protein, as a viroporin, has been implicated in membrane scission as E is present in virus particles at only a very low level and most is left associated with the ERGIC and cis Golgi consistent with a predominant role as a mediator of virus assembly and release at this location [111]. The lipid content at these locations may also enhance virus budding [112,113].

CoV membranes as antiviral targets

As CoVs cause such extensive membrane perturbation and as there is an acknowledged lack of available antiviral compounds to combat CoV-induced disease, it is not surprising that membrane rearrangement has been considered as a target for the development of inhibitors that could act as antivirals, along with the more classical targets of the polymerase and proteases [114]. Peptide therapeutics are promising antagonists in this regard as they compete directly for membrane binding or inhibit the conformational mechanisms involved and several peptides have been demonstrated to target various steps in the CoV replication cycle. A HR2 competitive peptide blocked the fusion mechanism of MERS-CoV and prevented virus entry when measured using a pseudotype assay [115] and a more complex S helix bundle, designed as a mimic of the final S fusion intermediate, was also active when measured similarly [116]. SARS-CoV has been inhibited similarly [117]. As membrane microdomains are implicated in CoV membrane interaction, drugs that alter microdomain composition, particularly the level of cholesterol present, have been shown to have an effect on some CoVs [118,119]. More general still is the use of drugs which alter intracellular vesicle pH and so inhibit the entry or exit of enveloped viruses, including CoVs [114,120]. Vaccines
and passive immunotherapy options have also targeted crucial CoV–membrane interactions. The predominant antibody response to S is to the S1 domain which has been shown to be a successful vaccine candidate [121,122] but the binding of antibodies directed here is subject to antigenic drift and may not be effective for all serotypes. The S2 domain by contrast is generally immunologically silent. Rare antibodies that do target S2 in the stem of S and inhibiting the fusion mechanism, are broadly reactive and so relatively impervious to serotype change [123]. The use of such broadly reactive monoclonal antibodies as therapies may be particularly suitable for the treatment of serious but sporadic CoV infections where general vaccination of the target population is not warranted or is impractical.

**Future perspective**

With their large, adaptable genomes and their extensive distribution in the biosphere, CoVs will certainly feature in future zoonotic outbreaks; SARS and MERS will not be the last. While vaccination remains the cornerstone of control for viral diseases, it is not quick, a new vaccine may take 15 years to develop and it is very virus specific, a MERS vaccine will not protect against SARS and vice versa. Similarly, antiviral drugs targeting the main enzyme functions of the virus risk being ineffective as a result of sequence variation in the target genes. Targeting the common physiological features of CoV replication; however, offers the possibility of developing panCoV treatments that focus on what is common to this family of viruses rather than what is distinct. There are obvious problems, viral stages that are so closely associated with host biology that toxicity would be expected, but there is also sufficient novelty, nsp-based membrane remodeling, for example, that clear targets for intervention exist. Such a strategy could offer the possibility for the development of panCoV agents of the future. More immediately, as membrane remodeling by CoVs is fundamental to immune evasion, targeting the proteins responsible for the remodeling could reveal the infection to the host immune system much sooner than would otherwise be the case and lead to the curtailment of the infection at a much earlier time, before extensive collateral damage is done. Together, a further understanding of the role of virus proteins in membrane interaction and remodeling, directly and via interaction with host factors, is likely to increase the underpinning data that lead to an increase in the therapeutic options for the control of CoV infections in the future.

**Executive summary**

- Coronaviruses (CoVs) are diverse, complex, adaptable viruses that have a significant impact on human health and animal productivity. Despite their diversity, common features exist, including the formation of membrane organelles which are driven by virus-encoded membrane-binding proteins.
- Both structural and nonstructural proteins of the virus contribute to membrane reorganization and viral protein interaction with membranes occurs at several stages of the virus replication cycle.
- The precise role of each protein and of individual domains within each protein in contacting the membrane and initiating its deformation remains work in progress and may vary across the family.
- Certainty has improved considerably for the structural proteins as a number of protein structures now exist, including structures for large molecules and multimeric assemblies such as the Spike protein trimer, obtained by cryoelectron microscopy. Models for the mechanism of protein function based on such structures allows them to be tested.
- Some certainty also applies to the nonstructural proteins in that certain combinations of proteins, notably nonstructural protein (nsp) 3, 4 and 6, can produce membrane deformation and structures that resemble those formed during virus infection. However, the precise contribution of each protein and the role of host proteins in the overall process remains to be determined. Ironically, it is the hydrophobic nature of the proteins concerned that makes them difficult targets for structural biology.
- Regardless of the precise mechanisms of membrane curvature the central role of membrane perturbation in the CoV replication cycle suggests itself as a target for designed intervention. A lack of membrane structures would clearly prevent virus replication but more reasonably even a partial inhibition might result in revelation of the replicative intermediates to the immune system and accelerate virus clearance.
- Study of the membrane reorganization associated with CoV infection is likely to contribute to a greater understanding of membrane biogenesis in general and to offer opportunities for rational design.
- As a universal feature of CoV replication, inhibition of membrane reorganization would likely apply to future zoonotic outbreak strains, as well as, to established and characterized viruses.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.

Open access
This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

References
Papers of special note have been highlighted as: ● of interest
1. Masters PS. The molecular biology of coronaviruses. Adv. Virus Res. 66, 193–292 (2006).
2. Gorbunova AE, Enjuanes L, Ziebuhr J, Snijder EJ. Nidovirales: evolving the largest RNA virus genome. Virus Res. 117(1), 17–37 (2006).
3. Adams MJ, Lelkowitz EJ, King AM et al. Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses (2016). Arch. Virol. 161(10), 2921–2949 (2016).
4. Drosten C, Gunther S, Preiser W et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348(20), 1967–1976 (2003).
5. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367(19), 1814–1820 (2012).
6. Baseler L, de Wit E, Feldmann H. A comparative review of animal models of middle east respiratory syndrome coronavirus infection. Vet. Pathol. 53(3), 521–531 (2016).
7. van Doremalen N, Munster VJ. Animal models of Middle East respiratory syndrome coronavirus infection. Antiviral Res. 122, 28–38 (2015).
8. Dent SD, Xia D, Wastling JM, Neuman BW, Maier HJ. The proteome of the infectious bronchitis virus Beau-R virion. J. Gen. Virol. 96(12), 3499–3506 (2015).
9. Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat. Rev. Microbiol. 7(6), 439–450 (2009).
10. Reguera J, Mudgal G, Santiago C, Casasnovas JM. A structural view of coronavirus-receptor interactions. Virus Res. 194, 3–15 (2014).
11. Hurst KR, Kuo L, Koetzner CA, Ye R, Hsue B, Masters PS. A major determinant for membrane protein interaction localizes to the carboxy-terminal domain of the mouse coronavirus nucleocapsid protein. J. Virol. 79(21), 13285–13297 (2005).
12. Klumperman J, Locker JK, Meijer AJ, Horzinek MC, Geuze HJ, Rottier PJ. Coronavirus M proteins accumulate in the Golgi complex beyond the site of virion budding. J. Virol. 68(10), 6523–6534 (1994).
13. de Haan CA, Stadler K, Godeke GJ, Bosch BJ, Rottier PJ. Cleavage inhibition of the murine coronavirus spike protein by a furin-like enzyme affects cell-cell but not virus-cell fusion. J. Virol. 78(11), 6048–6054 (2004).
14. Ulashi M, Verheije MH, de Haan CA, Reggiori F. Qualitative and quantitative ultrastructural analysis of the membrane rearrangements induced by coronavirus. Cell Microbiol. 12(6), 844–861 (2010).
15. Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 4(6), 1011–1033 (2012).
16. Sitzkowski SB, Whittaker GR. Dissecting virus entry via endocytosis. J. Gen. Virol. 83(Pt 7), 1535–1545 (2002).
17. Li F. Receptor recognition mechanisms of coronaviruses: a decade of structural studies. J. Virol. 89(4), 1954–1964 (2015).
18. Li F. Structure, function, and evolution of coronavirus spike proteins. Annu. Rev. Virol. 3(1), 237–261 (2016).
● A good starting point for anyone wishing to update themselves on the biology of the coronavirus Spike (S) protein and its interaction with the cell. Now supplemented by more recent cryo-electron microscopy structures that bring the descriptions of S up to the present day.
19. Raj VS, Mou H, Smits SL et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495(7440), 251–254 (2013).
20. Shirato K, Kawase M, Matsuyama S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J. Virol. 87(23), 12552–12561 (2013).
21. Du L, Yang Y, Zhou Y, Lu L, Li F, Jiang S. MERS-CoV spike protein: a key target for antivirals. Expert Opin. Ther. Targets 21(2), 131–143 (2017).
22. Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70, 777–810 (2001).
23. Burkard C, Verheije MH, Wicht O et al. Coronavirus cell entry occurs through the endo-lysosomal pathway in a proteolysis-dependent manner. PLoS Pathog. 10(11), e1004502 (2014).
24. Bosch BJ, van der Zee R, de Haan CA, Rottier PJ. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J. Virol. 77(16), 8801–8811 (2003).

25. Bosch BJ, Bartelink W, Rottier PJ, Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide. J. Virol. 82(17), 8887–8890 (2008).

26. Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc. Natl. Acad. Sci. USA 106(14), 5871–5876 (2009).

27. Madu IG, Roth SL, Belouzard S, Whittaker GR. Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide. J. Virol. 83(15), 7411–7421 (2009).

28. Millet JK, Goldstein ME, Labitz RN, Hsu HL, Daniel S, Whittaker GR. A camel-derived MERS-CoV with a variant spike protein cleavage site and distinct fusion activation properties. Emerg. Microbes Infect. 5(12), e126 (2016).

29. Millet JK, Whittaker GR. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res. 202, 120–134 (2015).

30. Lai AL, Millet JK, Daniel S, Freed JH, Whittaker GR. The SARS-CoV fusion peptide forms an extended bipartite fusion platform that perturbs membrane order in a calcium-dependent manner. J. Mol. Biol. 429(24), 3875–3892 (2017).

- In vitro data supporting the identification of the severe acute respiratory syndrome (SARS) S fusion peptide responsible for embedding S into the host cell membrane ahead of the collapse that draws the membranes together.

31. Chang KW, Sheng Y, Gombold JL. Coronavirus-induced membrane fusion requires the cysteine-rich domain in the spike protein. Virology 269(1), 212–224 (2000).

32. Kuo L, Godeke GJ, Raamsman MJ, Masters PS, Rottier PJ. Retargeting of coronavirus by substitution of the spike glycoprotein ectodomain: crossing the host cell species barrier. J. Virol. 74(3), 1393–1406 (2000).

33. Yao Q, Masters PS, Ye R. Negatively charged residues in the endodomain are critical for specific assembly of spike protein into murine coronavirus. Virology 442(1), 74–81 (2013).

34. Yang J, Lv J, Wang Y et al. Replication of murine coronavirus requires multiple cysteines in the endodomain of spike protein. Virology 427(2), 98–106 (2012).

35. Bosch BJ, de Haan CA, Smits SL, Rottier PJ. Spike protein assembly into the coronavirus: exploring the limits of its sequence requirements. Virology 334(2), 306–318 (2005).

36. Ye R, Montalto-Morrison C, Masters PS. Genetic analysis of determinants for spike glycoprotein assembly into murine coronavirus virions: distinct roles for charge-rich and cysteine-rich regions of the endodomain. J. Virol. 78(18), 9904–9917 (2004).

37. Gui M, Song W, Zhou H et al. Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. Cell Res. 27(1), 119–129 (2017).

38. Walls AC, Tortorici MA, Bosch BJ et al. Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature 531(7592), 114–117 (2016).

- The 3D structure of the S protein trimer of mouse hepatitis virus is notable for it being the complete molecule rather than the receptor binding domain previously solved.

39. Walls AC, Tortorici MA, Frenz B et al. Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy. Nat. Struct. Mol. Biol. 23(10), 899–905 (2016).

40. Yuan Y, Cao D, Zhang Y et al. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat. Commun. 8, 15092 (2017).

41. Torres J, Maheswari U, Parthasarathy K, Ng L, Liu DX, Gong X. Conductance and amantadine binding of a pore formed by a lysine-flanked transmembrane domain of SARS coronavirus envelope protein. Protein Sci. 16(9), 2065–2071 (2007).

42. Wilson L, Gage P, Ewart G. Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication. Virology 353(2), 294–306 (2006).

43. Liao Y, Yuan Q, Torres J, Tam JP, Liu DX. Biochemical and functional characterization of the membrane association and membrane permeabilizing activity of the severe acute respiratory syndrome coronavirus envelope protein. Virology 349(2), 264–275 (2006).

44. Boscarino JA, Logan HL, Lacny JJ, Gallagher TM. Envelope protein palmitoylations are crucial for murine coronavirus assembly. J. Virol. 82(6), 2989–2999 (2008).

45. Lopez LA, Riffle AJ, Pike SL, Gardner D, Hogue BG. Importance of conserved cysteine residues in the coronavirus envelope protein. J. Virol. 82(6), 3000–3010 (2008).

46. Tseng YT, Wang SM, Huang KJ, Wang CT. SARS-CoV envelope protein palmitoylation or nucleocapsid association is not required for promoting virus-like particle production. J. Virom. Sci. 21, 34 (2014).

47. Ruch TR, Machamer CE. The coronavirus E protein: assembly and beyond. Viruses 4(3), 363–382 (2012).

48. Vennema H, Godeke GJ, Rossen JW et al. Nucleocapsid-independent assembly of coronavirus-like particles by co-expression of viral envelope protein genes. EMBO J. 15(8), 2020–2028 (1996).
49. Chen SC, Lo SY, Ma HC, Li HC. Expression and membrane integration of SARS-CoV E protein and its interaction with M protein. 
    *Virus Genes* 38(3), 365–371 (2009).

50. Kuo L, Hurst-Hess KR, Koetzner CA, Masters PS. Analyses of coronavirus assembly interactions with interspecies membrane and 
    nucleocapsid protein chimeras. *J. Virol.* 90(9), 4357–4368 (2016).

51. Corse E, Machamer CE. Infectious bronchitis virus E protein is targeted to the Golgi complex and directs release of virus-like particles. 
    *J. Virol.* 74(9), 4319–4326 (2000).

52. Mortola E, Roy P. Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system. 
    *FEBS Lett.* 576(1–2), 174–178 (2004).

53. Madan V, Garcia Mde J, Sanz MA, Carrasco L. Viroporin activity of murine hepatitis virus E protein. *FEBS Lett.* 579(17), 3607–3612 
    (2005).

54. Ye Y, Hogue BG. Role of the coronavirus E viroporin protein transmembrane domain in virus assembly. *J. Virol.* 81(7), 3597–3607 
    (2007).

55. Castano-Rodriguez C, Honrubia JM, Gutierrez-Alvarez J et al. Role of severe acute respiratory syndrome coronavirus viroporins E, 3a, 
    and 8a in replication and pathogenesis. *MBio* 9(3), e02325–17 (2018).

56. Cohen JR, Lin LD, Machamer CE. Identification of a Golgi complex-targeting signal in the cytoplasmic tail of the severe acute 
    respiratory syndrome coronavirus envelope protein. *J. Virol.* 85(12), 5794–5803 (2011).

57. Teoh KT, Siu YL, Chan WL et al. The SARS coronavirus E protein interacts with PALS1 and alters tight junction formation and 
    epithelial morphogenesis. *Mol. Biol. Cell.* 21(22), 3838–3852 (2010).

58. Arndt AL, Larson BJ, Hogue BG. A conserved domain in the coronavirus membrane protein tail is important for virus assembly. 
    *J. Virol.* 84(21), 11418–11428 (2010).

59. Hogue BG, Machamer CE. Coronavirus structural proteins and virus assembly. In: *Nidoviruses*. Perlman S, Gallagher T, Snijder 
    E (Eds). ASM Press, Washington, DC 179–200 (2008).

60. Ujike M, Taguchi F. Incorporation of spike and membrane glycoproteins into coronavirus virions. *Viruses* 7(4), 1700–1725 (2015).

61. de Haan CA, Roestenberg P, de Wit M et al. Structural requirements for O-glycosylation of the mouse hepatitis virus membrane protein. 
    *J. Biol. Chem.* 273(45), 29905–29914 (1998).

62. Oostra M, de Haan CA, de Groot RJ, Rottier PJ. Glycosylation of the severe acute respiratory syndrome coronavirus triple-spanning 
    membrane proteins 3a and M. *J. Virol.* 80(5), 2326–2336 (2006).

63. Braakman I, van Anken E. Folding of viral envelope glycoproteins in the endoplasmic reticulum. *Traffic* 1(7), 533–539 (2000).

64. de Haan CA, de Wit M, Kuo L et al. The glycosylation status of the murine hepatitis coronavirus M protein affects the interferogenic 
    capacity of the virus in vitro and its ability to replicate in the liver but not the brain. *Virology* 312(2), 395–406 (2003).

65. Kuo L, Masters PS. Genetic evidence for a structural interaction between the carboxy termini of the membrane and nucleocapsid 
    proteins of mouse hepatitis virus. *J. Virol.* 76(10), 4987–4999 (2002).

66. Neuman BW, Buchmeier MJ. Supramolecular architecture of the coronavirus particle. *Adv. Virus Res.* 96, 1–27 (2016).

67. Neuman BW, Kiss G, Kunding AH et al. A structural analysis of M protein in coronavirus assembly and morphology. *J. Struct. Biol.* 
    174(1), 11–22 (2011).

68. van der Hoeven B, Oudshoorn D, Koster AJ, Snijder EJ, Rottier PJ. Mobility and interactions of coronavirus nonstructural 
    proteins of mouse hepatitis virus. *J. Virol.* 89(24), 12330–12340 (2015).

69. He Y, Xie Z, Dai J et al. Responses of the Toll-like receptor and melanoma differentiation-associated protein 5 signaling pathways to 
    avian infectious bronchitis virus infection in chicks. *Virology* 518, 57–68 (2016).

70. Lei J, Kuson Y, Hilgenfeld R. Nsp3 of coronaviruses: structures and functions of a large multi-domain protein. *Antiviral Res.* 149, 58–74 
    (2018).

* A timely update on the 200 kDa nsp3 and its encoded function some of which remain unknown.

71. Hagemeijer MC, Ulasi M, Vonk AM, Reggiori F, Rottier PJ, de Haan CA. Mobility and interactions of coronavirus nonstructural 
    protein 4. *J. Virol.* 85(9), 4572–4577 (2011).

72. Oostra M, te Lintelo EG, Deijs M, Verheije MH, Rottier PJ, de Haan CA. Localization and membrane topology of coronavirus 
    nonstructural protein 4: involvement of the early secretory pathway in replication. *J. Virol.* 81(22), 12323–12336 (2007).

73. Beachboard DC, Anderson-Daniels JM, Denison MR. Mutations across murine hepatitis virus nsp4 alter virus fitness and membrane 
    modifications. *J. Virol.* 89(4), 2080–2089 (2015).
Membrane binding proteins of coronaviruses

Review

76. Angelini MM, Akhlaghpour M, Neuman BW, Buchmeier MJ. Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles. MBio 4(4), e00524–13 (2013).

77. Reggiori F, Monastyrska I, Verheije MH et al. Coronaviruses hijack the LC3-I-positive EDEmosomes, ER-derived vesicles exporting short-lived ERAD regulators, for replication. Cell Host Microbe 7(6), 500–508 (2010).

78. Sakai Y, Kawachi K, Terada Y, Omori H, Matsuura Y, Kamitani W. Two-amino acids change in the nsp4 of SARS coronavirus abolishes viral replication. Virology 510, 165–174 (2017).

79. Al-Mulla HM, Turrell L, Smith NM et al. Competitive fitness in coronaviruses is not correlated with size or number of double-membrane vesicles under reduced-temperature growth conditions. MBio 5(2), e01107–e01113 (2014).

80. Maier HJ, Neuman BW, Bickerton E et al. Extensive coronavirus-induced membrane rearrangements are not a determinant of pathogenicity. Sci. Rep. 6, 27126 (2016).

81. Doyle N, Neuman BW, Simpson J et al. Infectious bronchitis virus nonstructural protein 4 alone induces membrane pairing. Virus 10(9), 477 (2018).

82. Baliji S, Cammer SA, Sobral B, Baker SC. Detection of nonstructural protein 6 in murine coronavirus-infected cells and analysis of the transmembrane topology by using bioinformatics and molecular approaches. J. Virol. 83(13), 6957–6962 (2009).

83. Cottam EM, Maier HJ, Manifava M et al. Coronavirus nsp6 proteins generate autophagosomes from the endoplasmic reticulum via an omegase intermediate. Autophagy 7(11), 1335–1347 (2011).

84. Cottam EM, Whelband MC, Wileman T. Coronavirus NSP6 restricts autophagosome expansion. Autophagy 10(8), 1426–1441 (2014).

85. Knoops K, Kikkert M, Worm SH et al. SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol. 6(9), e226 (2008).

86. Peter BJ, Kent HM, Mills IG et al. Viral rewiring of cellular lipid metabolism to create membranous replication compartments. MBio 4(5), e00801–00813 (2013).

87. Kooijman EE, Chupin V, de Kruijff B, Burger KN. Modulation of membrane curvature by phosphatidic acid and lysophosphatidic acid. Trends Biochem. Sci. 38(11), 10136–10141 (2004).

88. Quinteros JA, Markham PF, Lee SW et al. Analysis of the complete genomic sequences of two virus subpopulations of the Australian infectious bronchitis virus vaccine VicS. Avian Pathol. 44(5), 182–191 (2015).

89. Strating JR, van Kuppeveld FJ. Viral rewiring of cellular lipid metabolism to create membranous replication compartments. Curr. Opin. Cell Biol. 47, 24–33 (2017).

90. Stachowiak JC, Schmid EM, Ryan CJ et al. Membrane bending by protein-protein pairing. Nat. Cell Biol. 14(9), 944–949 (2012).
105. Lee MC, Orci L, Hamamoto S, Futai E, Ravazzola M, Schekman R. Sar1p N-terminal helix initiates membrane curvature and completes the fission of a COPII vesicle. *Cell* 122(4), 605–617 (2005).

106. Rossman JS, Jing X, Leser GP, Lamb RA. Influenza virus M2 protein mediates ESCRT-independent membrane scission. *Cell* 142(6), 902–913 (2010).

107. Welsch S, Muller B, Krausslich HG. More than one door - Budding of enveloped viruses through cellular membranes. *FEBS Lett.* 581(11), 2089–2097 (2007).

108. Trincone A, Schwegmann-Wessels C. Looking for a needle in a haystack: Cellular proteins that may interact with the tyrosine-based sorting signal of the TGEV S protein. *Virus Res.* 202, 3–11 (2015).

109. Weisz OA, Swift AM, Machamer CE. Oligomerization of a membrane protein correlates with its retention in the Golgi complex. *J. Cell. Biol.* 122(6), 1185–1196 (1993).

110. Tseng YT, Wang SM, Huang KJ, Lee AI, Chiang CC, Wang CT. Self-assembly of severe acute respiratory syndrome coronavirus membrane protein. *J. Biol. Chem.* 285(17), 12862–12872 (2010).

111. Venkatagopalan P, Daskalova SM, Lopez LA, Dolezal KA, Hogue BG. Coronavirus envelope (E) protein remains at the site of assembly. *Virology* 478, 75–85 (2015).

112. Schmitt AP, Lamb RA. Influenza virus assembly and budding at the viral bud zone. *Adv. Virus Res.* 64, 383–416 (2005).

113. Rossman JS, Lamb RA. Viral membrane scission. *Annu. Rev. Cell Dev. Biol.* 29, 551–569 (2013).

114. Dyall J, Gross R, Kindrachuk J et al. Middle east respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies. *Drug* 77(18), 1935–1966 (2017).

**An up-to-date review of the potential drug targets for these emerging pathogens.**

115. Gao J, Lu G, Qi J et al. Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. *J. Virol.* 87(24), 13134–13140 (2013).

116. Sun Y, Zhang H, Shi J, Zhang Z, Gong R. Identification of a novel inhibitor against Middle East respiratory syndrome coronavirus. *Viruses* 9(9), 255 (2017).

117. Sainz B Jr., Mossel EC, Gallaher WR et al. Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. *Virus Res.* 120(1–2), 146–155 (2006).

118. Jeon JH, Lee C. Cellular cholesterol is required for porcine nidovirus infection. *Arch. Virol.* 162(12), 3753–3767 (2017).

119. Yin J, Glende J, Schwegmann-Wessels C, Enjuanes L, Herrler G, Ren X. Cholesterol is important for a post-adsorption step in the entry process of transmissible gastroenteritis virus. *Antiviral Res.* 88(3), 311–316 (2010).

120. Dyall J, Coleman CM, Hart BJ et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. *Antimicrob. Agents Chemother.* 58(8), 4885–4893 (2014).

121. Jiaming L, Yanfeng Y, Yao D et al. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. *Vaccine* 35(1), 10–18 (2017).

122. Wirblich C, Coleman CM, Kurup D et al. One-Health: a safe, efficient, dual-use vaccine for humans and animals against middle east respiratory syndrome coronavirus and rabies virus. *J. Virol.* 91(2), e02040–16 (2017).

123. Elshabrawy HA, Coughlin MM, Baker SC, Prabhakar BS. Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing. *PLoS ONE* 7(11), e50366 (2012).